US4470111075 - Common Stock

We assign a fundamental rating of **3** out of 10 to **HUN**. **HUN** was compared to 85 industry peers in the **Chemicals** industry. **HUN** scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. **HUN** has a expensive valuation and it also scores bad on growth.

In the past year **HUN** was profitable.

In the past 5 years **HUN** has always been profitable.

The 3 year average ROIC (**6.65%**) for **HUN** is well above the current ROIC(**2.18%**). The reason for the recent decline needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.1% | ||

ROE | 2.38% | ||

ROIC | 2.18% |

ROA(3y)9.53%

ROA(5y)7.92%

ROE(3y)22.09%

ROE(5y)20.19%

ROIC(3y)6.65%

ROIC(5y)7.11%

The **Profit Margin** of **HUN** (**1.27%**) is worse than **65.88%** of its industry peers.

The **Operating Margin** of **HUN** (**2.64%**) is worse than **72.94%** of its industry peers.

Looking at the **Gross Margin**, with a value of **14.85%**, **HUN** is doing worse than **75.29%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **HUN** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 2.64% | ||

PM (TTM) | 1.27% | ||

GM | 14.85% |

OM growth 3Y14.48%

OM growth 5Y-3.58%

PM growth 3Y-11.49%

PM growth 5Y-9.2%

GM growth 3Y-1.77%

GM growth 5Y-4.39%

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), **HUN** is destroying value.

Compared to 1 year ago, **HUN** has less shares outstanding

Compared to 5 years ago, **HUN** has less shares outstanding

Compared to 1 year ago, **HUN** has a worse debt to assets ratio.

An Altman-Z score of **2.32** indicates that **HUN** is not a great score, but indicates only limited risk for bankruptcy at the moment.

The **Altman-Z score** of **HUN** (**2.32**) is comparable to the rest of the industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.44 | ||

Debt/FCF | 13.16 | ||

Altman-Z | 2.32 |

ROIC/WACC0.26

WACC8.4%

A Quick Ratio of **1.14** indicates that **HUN** should not have too much problems paying its short term obligations.

Looking at the **Quick ratio**, with a value of **1.14**, **HUN** is in line with its industry, outperforming **41.18%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.88 | ||

Quick Ratio | 1.14 |

The earnings per share for **HUN** have decreased strongly by **-85.23%** in the last year.

The **Earnings Per Share** has been growing slightly by **2.47%** on average over the past years.

The Revenue for **HUN** has decreased by **-25.07%** in the past year. This is quite bad

EPS 1Y (TTM)-85.23%

EPS 3Y21.62%

EPS 5Y2.47%

EPS growth Q2Q-78.87%

Revenue 1Y (TTM)-25.07%

Revenue growth 3Y5.68%

Revenue growth 5Y3.23%

Revenue growth Q2Q-25.11%

Based on estimates for the next years, **HUN** will show a decrease in **Earnings Per Share**. The EPS will decrease by **-6.87%** on average per year.

Based on estimates for the next years, **HUN** will show a small growth in **Revenue**. The Revenue will grow by **0.19%** on average per year.

EPS Next Y-74.87%

EPS Next 2Y-25.22%

EPS Next 3Y-6.87%

EPS Next 5YN/A

Revenue Next Year-24.05%

Revenue Next 2Y-9.23%

Revenue Next 3Y-3.43%

Revenue Next 5Y0.19%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

Based on the **Price/Earnings** ratio of **40.93**, the valuation of **HUN** can be described as expensive.

When comparing the **Price/Earnings** ratio of **HUN** to the average of the S&P500 Index (**24.97**), we can say **HUN** is valued expensively.

The **Price/Forward Earnings** ratio is **13.87**, which indicates a correct valuation of **HUN**.

When comparing the **Price/Forward Earnings** ratio of **HUN** to the average of the S&P500 Index (**20.05**), we can say **HUN** is valued slightly cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 40.93 | ||

Fwd PE | 13.87 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **HUN** is on the same level as its industry peers.

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **HUN** is on the same level as its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 36.41 | ||

EV/EBITDA | 11.31 |

PEG (NY)N/A

PEG (5Y)16.56

EPS Next 2Y-25.22%

EPS Next 3Y-6.87%

Compared to an average industry **Dividend Yield** of **3.89**, **HUN** pays a better dividend. On top of this **HUN** pays more dividend than 81.18% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.86% |

On average, the dividend of **HUN** grows each year by **11.25%**, which is quite nice.

Dividend Growth(5Y)11.25%

Div Incr Years3

Div Non Decr Years16

DP207.41%

EPS Next 2Y-25.22%

EPS Next 3Y-6.87%

**HUNTSMAN CORP**

NYSE:HUN (12/8/2023, 7:04:00 PM)

After market: 24.97 0 (0%)**24.97**

**-0.18 (-0.72%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.44B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.86% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 40.93 | ||

Fwd PE | 13.87 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)16.56

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.1% | ||

ROE | 2.38% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 2.64% | ||

PM (TTM) | 1.27% | ||

GM | 14.85% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.86

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.44 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.88 | ||

Quick Ratio | 1.14 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-85.23%

EPS 3Y21.62%

EPS 5Y

EPS growth Q2Q

EPS Next Y-74.87%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-25.07%

Revenue growth 3Y5.68%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y